Fresh from a $72M raise, Jeff Aronin's new lead rare disease drug is flagged as a failure
Just a few days after one of Jeff Aronin’s biotechs put out the word that they had raised $71.8 million to push their rare disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
